• 1
    Kyle RA, Gertz MA. Primary systemic amyloidosis: clinical and laboratory features in 474 cases. Semin Hematol 1995; 32: 4559.
  • 2
    Lachmann HJ, Goodman HJ, Gilbertson JA, Gallimore JR, Sabin CA, Gillmore JD et al. Natural history and outcome in systemic AA amyloidosis. N Engl J Med 2007; 356: 23612371.
  • 3
    Danesh F, Ho LT. Dialysis-related amyloidosis: history and clinical manifestations. Semin Dial 2001; 14: 8085.
  • 4
    Falk RH. Senile systemic amyloidosis: are regional differences real or do they reflect different diagnostic suspicion and use of techniques? Amyloid 2012; 19(Suppl 1): 6870.
  • 5
    Plante-Bordeneuve V, Said G. Familial amyloid polyneuropathy. Lancet Neurol 2011; 10: 10861097.
  • 6
    Gillmore JD, Lachmann HJ, Rowczenio D, Gilbertson JA, Zeng CH, Liu ZH et al. Diagnosis, pathogenesis, treatment, and prognosis of hereditary fibrinogen A alpha-chain amyloidosis. J Am Soc Nephrol 2009; 20: 444451.
  • 7
    Sattianayagam PT, Gibbs SD, Rowczenio D, Pinney JH, Wechalekar AD, Gilbertson JA et al. Hereditary lysozyme amyloidosis – phenotypic heterogeneity and the role of solid organ transplantation. J Intern Med 2012; 272: 3644.
  • 8
    Gillmore JD, Stangou AJ, Lachmann HJ, Goodman HJ, Wechalekar AD, Acheson J et al. Organ transplantation in hereditary apolipoprotein AI amyloidosis. Am J Transplant 2006; 6: 23422347.
  • 9
    Murphy CL, Wang S, Kestler D, Larsen C, Benson D, Weiss DT et al. Leukocyte chemotactic factor 2 (LECT2)-associated renal amyloidosis: a case series. Am J Kidney Dis 2010; 56: 11001107.
  • 10
    Pihlamaa T, Suominen S, Kiuru-Enari S. Familial amyloidotic polyneuropathy type IV – gelsolin amyloidosis. Amyloid 2012; 19(Suppl 1): 3033.
  • 11
    Merlini G, Wechalekar AD, Palladini G. Systemic light chain amyloidosis: an update for treating physicians. Blood 2013; 121: 51245130.
  • 12
    Pinney JH, Hawkins PN. Amyloidosis. Ann Clin Biochem 2012; 49: 229241.
  • 13
    Bartels H, Dikkers FG, van der Wal JE, Lokhorst HM, Hazenberg BP. Laryngeal amyloidosis: localized versus systemic disease and update on diagnosis and therapy. Ann Otol Rhinol Laryngol 2004; 113: 741748.
  • 14
    Pasternak S, White VA, Gascoyne RD, Perry SR, Johnson RL, Rootman J. Monoclonal origin of localised orbital amyloidosis detected by molecular analysis. Br J Ophthalmol 1996; 80: 10131017.
  • 15
    Goodman HJ, Bridoux F, Lachmann HJ, Gilbertson J, Gallimore JR, Joshi J et al. Localised amyloidosis: clinical features and outcome in 235 cases. Haematologica 2005; 90: 203a.
  • 16
    Puchtler H, Sweat F, Levine M. On the binding of Congo red by amyloid. J Histochem Cytochem 1962; 10: 355364.
  • 17
    Highman B. Improved methods for demonstrating amyloid in paraffin sections. Arch Pathol (Chic) 1946; 41: 559562.
  • 18
    Picken MM, Hazenberg BPC, Obici L. Report from the diagnostic interactive session. In: Skinner M , Berk JL , Connors LH , Seldin DC , eds. XIth International Symposium on Amyloidosis. Boca Raton, FL: CRC Press; 2008; 377382.
  • 19
    Pepys MB, Booth DR, Hutchinson WL, Gallimore JR, Collins IM, Hohenester E. Amyloid P component. A critical review. Amyloid 1997; 4: 274295.
  • 20
    Cohen AS, Calkins E. Electron microscopic observations on a fibrous component in amyloid of diverse origins. Nature 1959; 183: 12021203.
  • 21
    Herrera GA, Turbat-Herrera EA. Renal diseases with organized deposits: an algorithmic approach to classification and clinicopathologic diagnosis. Arch Pathol Lab Med 2010; 134: 512531.
  • 22
    Leung N, Bridoux F, Hutchison CA, Nasr SH, Cockwell P, Fermand JP et al. Monoclonal gammopathy of renal significance: when MGUS is no longer undetermined or insignificant. Blood 2012; 120: 42924295.
  • 23
    Gertz MA, Merlini G, Treon SP. Amyloidosis and Waldenstrom's macroglobulinemia. Hematology Am Soc Hematol Educ Program 2004; 257282.
  • 24
    van Gameren II, Hazenberg BP, Bijzet J, van Rijswijk MH. Diagnostic accuracy of subcutaneous abdominal fat tissue aspiration for detecting systemic amyloidosis and its utility in clinical practice. Arthritis Rheum 2006; 54: 20152021.
  • 25
    Halloush RA, Lavrovskaya E, Mody DR, Lager D, Truong L. Diagnosis and typing of systemic amyloidosis: the role of abdominal fat pad fine needle aspiration biopsy. CytoJournal 2009; 6: 24.
  • 26
    Hazenberg BPC. Groningen unit for amyloidosis research & development [homepage on the Internet]. Investigations. Groningen. 2011. [updated 2011 Oct 29; cited 2013 Jan 9]. Available from URL:
  • 27
    Comenzo RL, Reece D, Palladini G, Seldin D, Sanchorawala V, Landau H et al. Consensus guidelines for the conduct and reporting of clinical trials in systemic light-chain (AL) amyloidosis. Leukemia 2012; 26: 23172325.
  • 28
    Maceira AM, Prasad SK, Hawkins PN, Roughton M, Pennell DJ. Cardiovascular magnetic resonance and prognosis in cardiac amyloidosis. J Cardiovasc Magn Reson 2008; 10: 54.
  • 29
    Perugini E, Rapezzi C, Piva T, Leone O, Bacchi-Reggiani L, Riva L et al. Non-invasive evaluation of the myocardial substrate of cardiac amyloidosis by gadolinium cardiac magnetic resonance. Heart 2006; 92: 343349.
  • 30
    Jacobson DR, Pastore RD, Yaghoubian R, Kane I, Gallo G, Buck FS et al. Variant-sequence transthyretin (isoleucine 122) in late-onset cardiac amyloidosis in black Americans. N Engl J Med 1997; 336: 466473.
  • 31
    Lane SW, Goodman HJ, Francis L, Bofinger A, Mollee PN. Hereditary fibrinogen A alpha-chain amyloidosis. Pathology 2006; 38: 380382.
  • 32
    Hawkins PN. Serum amyloid P component scintigraphy for diagnosis and monitoring amyloidosis. Curr Opin Nephrol Hypertens 2002; 11: 649655.
  • 33
    Hutt DF, Page J, Lachmann HJ, Gillmore J, Whelan C, Gibbs SD et al. 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid (99mTc DPD) scintigraphy in 171 patients with suspected systemic amyloidosis. In: Hazenberg B , ed. XIIIth International Symposium on Amyloidosis. Groningen: University Medical Center Groningen; 2012; 4445.
  • 34
    Suan D, Hughan M, Bates S, Rochtchina E, Empson M, Mitchell P et al. Prevalence of paraproteinaemia in older Australians. Intern Med J 2012; 42: 165169.
  • 35
    Lachmann HJ, Booth DR, Booth SE, Bybee A, Gilbertson JA, Gillmore JD et al. Misdiagnosis of hereditary amyloidosis as AL (primary) amyloidosis. N Engl J Med 2002; 346: 17861791.
  • 36
    Palladini G, Russo P, Bosoni T, Verga L, Sarais G, Lavatelli F et al. Identification of amyloidogenic light chains requires the combination of serum-free light chain assay with immunofixation of serum and urine. Clin Chem 2009; 55: 499504.
  • 37
    Satoskar AA, Burdge K, Cowden DJ, Nadasdy GM, Hebert LA, Nadasdy T. Typing of amyloidosis in renal biopsies: diagnostic pitfalls. Arch Pathol Lab Med 2007; 131: 917922.
  • 38
    Satoskar AA, Efebera Y, Hasan A, Brodsky S, Nadasdy G, Dogan A et al. Strong transthyretin immunostaining: potential pitfall in cardiac amyloid typing. Am J Surg Pathol 2011; 35: 16851690.
  • 39
    Picken MM. Amyloidosis – where are we now and where are we heading? Arch Pathol Lab Med 2010; 134: 545551.
  • 40
    Arbustini E, Verga L, Concardi M, Palladini G, Obici L, Merlini G. Electron and immuno-electron microscopy of abdominal fat identifies and characterizes amyloid fibrils in suspected cardiac amyloidosis. Amyloid 2002; 9: 108114.
  • 41
    Hood BL, Darfler MM, Guiel TG, Furusato B, Lucas DA, Ringeisen BR et al. Proteomic analysis of formalin-fixed prostate cancer tissue. Mol Cell Proteomics 2005; 4: 17411753.
  • 42
    Loo D, Mollee PN, Renaut P, Hill MM. Proteomics in molecular diagnosis: typing of amyloidosis. J Biomed Biotechnol 2011; 2011: 754109.
  • 43
    Vrana JA, Gamez JD, Madden BJ, Theis JD, Bergen HR, 3rd, Dogan A. Classification of amyloidosis by laser microdissection and mass spectrometry-based proteomic analysis in clinical biopsy specimens. Blood 2009; 114: 49574959.
  • 44
    Driver E , Kidd D , Mapps J , eds. Anatomica: The Complete Home Medical Reference. Richmond Hill, Ont.: Firefly Books; 2010.